MacroGenics Co-Founder Koenig Stepping Down as President, CEO

Dow Jones

Oct 30, 2024

By Colin Kellaher

MacroGenics on Wednesday said its co-founder and longtime leader, Scott Koenig, is leaving the biopharmaceutical company.

The Rockville, Md., company said Koenig plans to step down as president and chief executive early next year, and that its board has hired Heidrick & Struggles to lead the search for a new CEO.

MacroGenics said it has signed a separation agreement with Koenig effective at the end of February that includes continued payment of his annual salary and target bonus for two years.

Koenig, who helped found MacroGenics in 2000 and has been president, CEO and a board member since September 2001, received a salary of nearly $705,000 and total compensation of more than $3.7 million in 2023.

MacroGenics on Wednesday said Koenig has agreed to resign from the board and will serve as an adviser through February 2030 in exchange for the continued vesting of any unvested stock-option and restricted stock unit awards.

The company said its board has formed a special committee to oversee the executive transition process.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 30, 2024 09:50 ET (13:50 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2479509785"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479509785\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2479509785?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 21:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479509785","market":"fut","top_or_hot":-1,"title":"MacroGenics Co-Founder Koenig Stepping Down as President, CEO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  MacroGenics on Wednesday said its co-founder and longtime leader, Scott Koenig, is leaving the biopharmaceutical company. \n</p>\n<p>\n  The Rockville, Md., company said Koenig plans to step down as president and chief executive early next year, and that its board has hired Heidrick &amp; Struggles to lead the search for a new CEO. \n</p>\n<p>\n  MacroGenics said it has signed a separation agreement with Koenig effective at the end of February that includes continued payment of his annual salary and target bonus for two years. \n</p>\n<p>\n  Koenig, who helped found MacroGenics in 2000 and has been president, CEO and a board member since September 2001, received a salary of nearly $705,000 and total compensation of more than $3.7 million in 2023. \n</p>\n<p>\n  MacroGenics on Wednesday said Koenig has agreed to resign from the board and will serve as an adviser through February 2030 in exchange for the continued vesting of any unvested stock-option and restricted stock unit awards. \n</p>\n<p>\n  The company said its board has formed a special committee to oversee the executive transition process. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2024 09:50 ET (13:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MacroGenics Co-Founder Koenig Stepping Down as President, CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMacroGenics Co-Founder Koenig Stepping Down as President, CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-10-30 21:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  MacroGenics on Wednesday said its co-founder and longtime leader, Scott Koenig, is leaving the biopharmaceutical company. \n</p>\n<p>\n  The Rockville, Md., company said Koenig plans to step down as president and chief executive early next year, and that its board has hired Heidrick &amp; Struggles to lead the search for a new CEO. \n</p>\n<p>\n  MacroGenics said it has signed a separation agreement with Koenig effective at the end of February that includes continued payment of his annual salary and target bonus for two years. \n</p>\n<p>\n  Koenig, who helped found MacroGenics in 2000 and has been president, CEO and a board member since September 2001, received a salary of nearly $705,000 and total compensation of more than $3.7 million in 2023. \n</p>\n<p>\n  MacroGenics on Wednesday said Koenig has agreed to resign from the board and will serve as an adviser through February 2030 in exchange for the continued vesting of any unvested stock-option and restricted stock unit awards. \n</p>\n<p>\n  The company said its board has formed a special committee to oversee the executive transition process. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2024 09:50 ET (13:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MGNX","symbol_name":"MacroGenics Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479509785","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479509785","pubTimestamp":1730296200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"MacroGenics on Wednesday said its co-founder and longtime leader, Scott Koenig, is leaving the biopharmaceutical company.The Rockville, Md., company said Koenig plans to step down as president and chief executive early next year, and that its board has hired Heidrick & Struggles to lead the search for a new CEO.MacroGenics said it has signed a separation agreement with Koenig effective at the end of February that includes continued payment of his annual salary and target bonus for two years.Koenig, who helped found MacroGenics in 2000 and has been president, CEO and a board member since September 2001, received a salary of nearly $705,000 and total compensation of more than $3.7 million in 2023.MacroGenics on Wednesday said Koenig has agreed to resign from the board and will serve as an adviser through February 2030 in exchange for the continued vesting of any unvested stock-option and restricted stock unit awards.The company said its board has formed a special committee to oversee the","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MGNX":"MacroGenics Inc.","BK4139":"生物科技"},"translate_title":"MacroGenics联合创始人Koenig辞去总裁兼首席执行官职务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MGNX":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  MacroGenics on Wednesday said its co-founder and longtime leader, Scott Koenig, is leaving the biopharmaceutical company. \n\n\n  The Rockville, Md., company said Koenig plans to step down as president and chief executive early next year, and that its board has hired Heidrick & Struggles to lead the search for a new CEO. \n\n\n  MacroGenics said it has signed a separation agreement with Koenig effective at the end of February that includes continued payment of his annual salary and target bonus for two years. \n\n\n  Koenig, who helped found MacroGenics in 2000 and has been president, CEO and a board member since September 2001, received a salary of nearly $705,000 and total compensation of more than $3.7 million in 2023. \n\n\n  MacroGenics on Wednesday said Koenig has agreed to resign from the board and will serve as an adviser through February 2030 in exchange for the continued vesting of any unvested stock-option and restricted stock unit awards. \n\n\n  The company said its board has formed a special committee to oversee the executive transition process. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2024 09:50 ET (13:50 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}